ArticleCureus2026
Serum 17β-Estradiol Concentrations in Women With Interstitial Cystitis/Bladder Pain Syndrome: A Retrospective Observational Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionInterstitial cystitis/bladder pain syndrome (IC/BPS) is a long-lasting, sterile inflammatory disease affecting the lower urinary tract, marked by pelvic pain, urgency, and nighttime urination (nocturia). The marked female predominance of IC/BPS has prompted interest in the potential role of endocrine factors in disease susceptibility and symptom variability. However, the relationship between circulating estrogen concentrations and IC/BPS remains incompletely understood, and clinical evidence has been inconsistent. This study aimed to characterize the baseline distribution of serum 17β-estradiol concentrations among women diagnosed with IC/BPS. METHODOLOGY: We conducted a retrospective, observational, single-center study of 195 women with a confirmed diagnosis of IC/BPS according to European Association of Urology (EAU) and American Urological Association (AUA) criteria. Serum 17β-estradiol concentrations obtained during the initial clinical evaluation were retrieved from medical records. Hormone concentrations were categorized using established physiological reference intervals, and descriptive statistics summarized the distribution of serum estradiol levels.
resultsA total of 195 women were included in the study. Serum estradiol concentrations ranged from 3.1 to 712.7 pg/mL, with a median of 40.2 pg/mL and a mean of 68.7 ± 89.5 pg/mL. Overall, 109 patients (55.9%) had serum estradiol concentrations below 50 pg/mL, 43 (22.1%) between 51 and 100 pg/mL, 30 (15.4%) between 101 and 200 pg/mL, and 13 (6.6%) above 200 pg/mL.
conclusionsLow serum 17β-estradiol concentrations were frequently observed in this cohort of women with IC/BPS. Although these findings are consistent with the hypothesis that endocrine factors may contribute to disease heterogeneity, the retrospective observational design and the absence of a healthy control group preclude conclusions about causality or clinical application. Prospective longitudinal studies incorporating standardized hormone assessment, appropriate control groups, and adjustment for potential confounding variables are needed to clarify the role of circulating estradiol in IC/BPS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.